N-{4-[(3-nitrobenzyl)oxy]phenyl}acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{4-[(3-nitrobenzyl)oxy]phenyl}acetamide
• 英文别名: N-[4-[(3-nitrophenyl)methoxy]phenyl]acetamide
• 化学式: C₁₅H₁₄N₂O₄
• 分子量: 286.287
• InChiKey: UTCCZNFVURIWFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-{4-[(3-nitrobenzyl)oxy]phenyl}acetamide 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 反应 0.5h， 生成 4-(4-nitrobenzyloxy)aniline
  参考文献：
  名称：

  Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)- N -phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors

  摘要：

  Human sirtuin 2 (SIRT2) plays pivotal roles in multiple biological processes such as cell cycle regulation, autophagy, immune and inflammatory responses. Dysregulation of SIRT2 was considered as a main aspect contributing to several human diseases, including cancer. Development of new potent and selective SIRT2 inhibitors is currently desirable, which may provide a new strategy for treatment of related diseases. Herein, a structure-based optimization approach led to new 2-((4,6-dimethylpyrimidin-2-yl) thio)-N-phenylacetamide derivatives as SIRT2 inhibitors. SAR analyses with new synthesized derivatives revealed a number of new potent SIRT2 inhibitors, among which 28e is the most potent inhibitor with an IC50 value of 42 nM. The selectivity analyses found that 28e has a very good selectivity to SIRT2 over SIRT1 and SIRT3. In cellular assays, 28e showed a potent ability to inhibit human breast cancer cell line MCF-7 and increase the acetylation of alpha-tubulin in a dose-dependent manner. This study will aid further efforts to develop highly potent and selective SIRT2 inhibitors for the treatment of cancer and other related diseases. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.04.010
• 作为产物：
  描述：

  对乙酰氨基酚 、 3-硝基溴苄 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以81%的产率得到N-{4-[(3-nitrobenzyl)oxy]phenyl}acetamide
  参考文献：
  名称：

  X射线晶体结构指导发现新的选择性，模拟底物的sirtuin 2抑制剂的发现，该抑制剂具有针对非小细胞肺癌细胞的活性

  摘要：

  人sirtuin 2（SIRT2）是烟酰胺腺嘌呤二核苷酸（NAD +）依赖性脱酰基酶，与人类疾病（包括癌症）有关。寻找用于SIRT2的选择性小分子抑制剂作为化学工具和潜在的治疗剂。在这里，我们报告了新的N-（3-（苯氧基甲基）苯基）乙酰胺衍生物与SIRT2的X射线晶体结构指导的结构-活性关系研究，从而鉴定了有效的，选择性的SIRT2抑制剂。晶体学分析表明，新的抑制剂通过诱导扩大的疏水口袋的形成，特别是模仿肉豆蔻酰化赖氨酸底物的相互作用而起作用。最有效的抑制剂24a可以剂量依赖性地提高非小细胞肺癌H441细胞中α-微管蛋白的乙酰化水平，该蛋白具有较高的SIRT2表达水平（通过Western印迹分析确定）。进一步的细胞分析表明，24a主要通过抑制细胞增殖而不是诱导细胞凋亡来抑制细胞生长。此外，24a可以抑制H441细胞的迁移和侵袭。这些结果为进一步开发新的有效，选择性和具有细胞活性的SIRT2

  DOI：

  10.1016/j.ejmech.2018.06.041

文献信息

• Design, Synthesis and Biological Evaluation of Salicylamide Analogues as Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
  作者：Yang Liu、Yijing Li、Jianzhen Liu、Limin Yang、Pengzhan Li、Guisen Zhao

  DOI：10.2174/1570180812666150819003111

  日期：2016.3.3

  Blocking epidermal growth factor receptor (EGFR) has been the hotspot in the field of cancer therapy. Based on the fact that salicylanilides possess well inhibitory activity against EGFR tyrosine kinase, a series of salicylamide analogs bearing 4’-substitution were designed to explore new candidates exhibiting improved efficacy against EGFR. Many of the synthesized compounds inhibited EGFR in the micromolar

  阻断表皮生长因子受体（EGFR）已成为癌症治疗领域的热点。基于水杨酰苯胺对EGFR酪氨酸激酶具有良好的抑制活性这一事实，设计了一系列带有4'取代的水杨酰胺类似物，以探索对EGFR表现出更高疗效的新候选药物。许多合成的化合物在微摩尔范围内抑制EGFR，尤其是化合物15a和15b（IC 50分别为0.27μM和1.1μM）。我们报告我们的发现，作为进一步发展作为EGFR抑制剂的水杨酰胺类似物的基础。
• 一类SIRT2蛋白抑制剂及其在制药中的用途
  申请人：西华大学

  公开号：CN106543088B

  公开（公告）日：2019-03-29

  本发明公开了式Ⅰ所示的化合物或其药学上可接受的盐、晶型、溶剂合物：其中，X选自等；R1选自芳基、杂芳基、取代芳基、取代杂芳基或R2选自R3选自卤素、C1～C4烷基或C1～C4烷氧基。本发明式Ⅰ所示的新化合物，不仅对SIRT2具有良好的抑制活性，而且对肿瘤具有很好的抑制作用，具有很好的药用潜力，为临床用药提供了一种新的潜在选择。
• Identification of novel aza-analogs of TN-16 as disrupters of microtubule dynamics through a multicomponent reaction
  作者：Arash Foroutan、Marco Corazzari、Ambra A. Grolla、Giorgia Colombo、Cristina Travelli、Armando A. Genazzani、Sewan Theeramunkong、Ubaldina Galli、Gian Cesare Tron

  DOI：10.1016/j.ejmech.2022.114895

  日期：2023.1

  prepare TN-16, and then we applied the same reaction for the synthesis of aza-analogs. In brief, we prepared a library of 62 novel compounds, and three of these retained nanomolar potencies. TN-16 and the active analogs are cytotoxic on cancer cell lines and, as expected from antitubulin agents, induce G2/M cell cycle arrest. These agents lead to a disruption of the microtubules and an increase in α-tubulin

  尽管新的生物靶标以惊人的速度出现在抗癌治疗中，但抗微管蛋白药物仍然是众多肿瘤学方案的支柱，其疗效已在多种成人和儿童癌症中得到证实。在目前的贡献中，我们着手开发一种有效但被忽视的抗微管蛋白剂 TN-16 的类似物，TN-16 最初是通过修饰 tenuazonic 酸（3-乙酰基-5-仲丁基四酸）发现的。 为此，我们开发了一种新的多组分反应来制备 TN-16，然后我们将相同的反应应用于合成氮杂类似物。简而言之，我们准备了一个包含 62 种新化合物的库，其中三种保留了纳摩尔级别的效力。TN-16 和活性类似物对癌细胞系具有细胞毒性，并且正如抗微管蛋白药物预期的那样，诱导 G 2 /M 细胞周期停滞。这些试剂会导致微管破坏和 α-微管蛋白乙酰化增加并影响体外聚合，尽管它们在细胞微管蛋白聚合测定中的影响较小。
• Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)- N -phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors
  作者：Lingling Yang、Xiaobo Ma、Chen Yuan、Yanying He、Ling Li、Sha Fang、Wei Xia、Tao He、Shan Qian、Zhihong Xu、Guobo Li、Zhouyu Wang

  DOI：10.1016/j.ejmech.2017.04.010

  日期：2017.7

  Human sirtuin 2 (SIRT2) plays pivotal roles in multiple biological processes such as cell cycle regulation, autophagy, immune and inflammatory responses. Dysregulation of SIRT2 was considered as a main aspect contributing to several human diseases, including cancer. Development of new potent and selective SIRT2 inhibitors is currently desirable, which may provide a new strategy for treatment of related diseases. Herein, a structure-based optimization approach led to new 2-((4,6-dimethylpyrimidin-2-yl) thio)-N-phenylacetamide derivatives as SIRT2 inhibitors. SAR analyses with new synthesized derivatives revealed a number of new potent SIRT2 inhibitors, among which 28e is the most potent inhibitor with an IC50 value of 42 nM. The selectivity analyses found that 28e has a very good selectivity to SIRT2 over SIRT1 and SIRT3. In cellular assays, 28e showed a potent ability to inhibit human breast cancer cell line MCF-7 and increase the acetylation of alpha-tubulin in a dose-dependent manner. This study will aid further efforts to develop highly potent and selective SIRT2 inhibitors for the treatment of cancer and other related diseases. (C) 2017 Elsevier Masson SAS. All rights reserved.
• X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells
  作者：Ling-Ling Yang、Hua-Li Wang、Lei Zhong、Chen Yuan、Si-Yu Liu、Zhu-Jun Yu、Sha Liu、Yu-Hang Yan、Chengyong Wu、Yuxi Wang、Zhouyu Wang、Yamei Yu、Qiang Chen、Guo-Bo Li

  DOI：10.1016/j.ejmech.2018.06.041

  日期：2018.7

  cancer. Selective small-molecule inhibitors for SIRT2 are sought as chemical tools and potential therapeutics. Here we report the X-ray crystal structure guided structure-activity relationship studies of new N-(3-(phenoxymethyl)phenyl)acetamide derivatives with SIRT2, which led to the identification of potent, selective SIRT2 inhibitors. Crystallographic analyses reveal that the new inhibitors act via

  人sirtuin 2（SIRT2）是烟酰胺腺嘌呤二核苷酸（NAD +）依赖性脱酰基酶，与人类疾病（包括癌症）有关。寻找用于SIRT2的选择性小分子抑制剂作为化学工具和潜在的治疗剂。在这里，我们报告了新的N-（3-（苯氧基甲基）苯基）乙酰胺衍生物与SIRT2的X射线晶体结构指导的结构-活性关系研究，从而鉴定了有效的，选择性的SIRT2抑制剂。晶体学分析表明，新的抑制剂通过诱导扩大的疏水口袋的形成，特别是模仿肉豆蔻酰化赖氨酸底物的相互作用而起作用。最有效的抑制剂24a可以剂量依赖性地提高非小细胞肺癌H441细胞中α-微管蛋白的乙酰化水平，该蛋白具有较高的SIRT2表达水平（通过Western印迹分析确定）。进一步的细胞分析表明，24a主要通过抑制细胞增殖而不是诱导细胞凋亡来抑制细胞生长。此外，24a可以抑制H441细胞的迁移和侵袭。这些结果为进一步开发新的有效，选择性和具有细胞活性的SIRT2